rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Aardvark Therapeutics, Inc.

AARD · Nasdaq

Health CareBiotechnologyNot moving yet

AARD stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 28.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 36
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$145K
Insider sales, 12 months
$790K
Officials’ trades on record
0
Institutions holding
71 (-6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$22.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months2
Buyers · sellers2 · 1
WhoDidSharesTraded
Nelson SunOfficersold62,000at $5.1811 Sep 2026filed 11 Sep 2026
Nelson SunOfficersold14,754at $5.0010 Sep 2026filed 11 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders71-6 on the quarter
New · exited19 · 25
Reported value$54.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Decheng Capital LLCunchanged · filed 14 Aug 20263,917,299$22.6M00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 20261,283,166$7.4M+40,389+3.2%
Laurion Capital Management LPunchanged · filed 13 Aug 20261,034,459$6.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026562,877$3.2M+8,776+1.6%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026480,249$2.8M+345,754+257.1%
EcoR1 Capital, LLCnew · filed 14 Aug 2026396,194$2.3M+396,194
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026300,000$1.7M00.0%
BlackRock, Inc.reduced · filed 7 Aug 2026187,045$1.1M-605,526−76.4%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026149,844$864K-159,605−51.6%
CANTOR FITZGERALD, L. P.added · filed 14 Aug 2026116,582$672K+49,900+74.8%
31 Mar 2025 – 30 Jun 2026
295275Mar 25Jun 25Dec 25Mar 26Jun 26

News

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalfmykxlg.com · 19 Oct 2026Class Action Lawsuit Alert: Levi & Korsinsky Reminds Aardvark Therapeutics, ...pr-inside.com · 13 Oct 2026Levi & Korsinsky Urges Aardvark Therapeutics, Inc. (AARD) Shareholders ...pr-inside.com · 12 Oct 2026AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, ...pr-inside.com · 9 Oct 2026Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directorsmanilatimes.net · 8 Oct 2026Class Action Lawsuit Filed: Aardvark Therapeutics, Inc. (AARD) - Join ...pr-inside.com · 30 Sep 2026AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit ...gazettextra.com · 21 Sep 2026Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class ...pr-inside.com · 21 Sep 2026

Everyone who traded it

Zhongwei Zhang Company insiderDirector · last 7 Oct 20260 · 0
Nelson Sun Company insiderOfficer · last 11 Sep 20263 · 2
Jeffrey Chi Company insiderDirector · last 14 Aug 20260 · 0
Roy D. Baynes Company insiderDirector · last 14 Aug 20260 · 0
Susan E. Graf Company insiderDirector · last 14 Aug 20260 · 0
Victor Edward Tong Jr. Company insiderDirector · last 14 Aug 20260 · 0
Manasi Jaiman Company insiderChief Medical Officer · last 9 Feb 20260 · 0
Tien-Li Lee Company insiderChief Executive Officer · last 9 Feb 20266 · 0
Bryan Jones Company insiderChief Operating Officer · last 15 Oct 20250 · 0
Bihua Chen Company insiderOther · last 14 Feb 20251 · 0
Decheng Capital Global Life Sciences Fund Iv, L.p. Company insider10% owner · last 14 Feb 20251 · 0
Vickers Venture Fund Vi Pte Ltd Company insider10% owner · last 14 Feb 20250 · 0

Same industry

MRNA ModernaLeading+154%
IOVA Iovance BiotherapeuticsLeading+133%
ABCL AbCellera BiologicsLeading+61%
ENTX Entera BioLeading+49%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+46%
HELP Helus PharmaLeading+37%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-58.8%
Share count trendFY 2025 · to 28 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$47.1M
Free cash flowFY 2025 · to 31 Dec 2025−$54.3M

Analyst forecasts

No analyst forecasts yet.